Epidermal growth factor receptor and variant III targeted immunotherapy

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma

(2014) Hongsheng Miao et al.   PLoS One

EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma

(2013) Qi-Wen Fan et al.   CANCER CELL

Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy

(2013) V. Chandramohan et al.   CLINICAL CANCER RESEARCH

EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

(2013) J. H. Sampson et al.   CLINICAL CANCER RESEARCH

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma

(2013) Bryan D. Choi et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

(2012) Richard A. Morgan et al.   HUMAN GENE THERAPY

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma

(2012) B. D. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases

(2011) Véronique Corbière et al.   CANCER RESEARCH

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma

(2010) Angel Casaco et al.   CANCER BIOLOGY & THERAPY

Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy

(2010) J. J. Hong et al.   CLINICAL CANCER RESEARCH

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

(2010) M.-d.-M. Inda et al.   GENES & DEVELOPMENT

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial

(2010) Renier Brentjens et al.   MOLECULAR THERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma

(2009) B. Neyns et al.   ANNALS OF ONCOLOGY

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

(2009) J. H. Sampson et al.   MOLECULAR CANCER THERAPEUTICS

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells

(2008) Khalid Al-Nedawi et al.   NATURE CELL BIOLOGY

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors

(2008) John H. Sampson et al.   NEURO-ONCOLOGY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE